Bifidobacterium bifidum TMC3115 Can Characteristically Influence Glucose and Lipid Profile and Intestinal Microbiota in
- PDF / 2,890,916 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 5 Downloads / 195 Views
Bifidobacterium bifidum TMC3115 Can Characteristically Influence Glucose and Lipid Profile and Intestinal Microbiota in the Middle-Aged and Elderly Ke Wang 1 & Xiaohong Yu 1 & Yi Li 2 & Yun Guo 2 & Lin Ge 1 & Fangfang Pu 1 & Xinying Ma 3 & Wenjing Cui 3 & Francesco Marrota 4 & Fang He 1,5 & Ming Li 1,5
# Springer Science+Business Media, LLC, part of Springer Nature 2018
Abstract Bifidobacterium bifidum TMC3115 strain (TMC3115) was orally administrated to 47 subjects with mild hyperglycaemia and dyslipidaemia aged 45 to 75 years for 3 weeks. Blood samples were collected before and after intervention for profiling plasma total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol and triglyceride concentrations, as well as fasting blood glucose. Before and 3 and 4 weeks after intervention, the faecal samples were collected to analyse faecal microbiota using the sequencing of 16S rRNA genes with a next-generation sequencer. TMC3115 significantly decreased plasma TC and LDL-C levels of the tested subjects after intervention (P < 0.05). The frequencies of defaecation and faecal odour after the intervention and 1 week later were significantly better than at pre-intervention, respectively. TMC3115 administration increased Firmicutes, Bacteroides and Actinobacteria and decreases in Proteobacteria and Fusobacteria. There were significant increases in the proportions of Dorea and Lachnospira after the intervention (P < 0.05). TMC3115 also increased the level of Firmicutes and decreased that of Bacteroidetes 1 week after the intervention (P < 0.05). Serum triglycerides correlated negatively with the proportions of Bacteroidetes (R = − 0.21, P = 0.047) and Bacteroides (R = − 0.23, P = 0.029), while the relative abundance of Dialister of Firmicutes correlated negatively and significantly with the serum LDL-C (R = − 0.24, P = 0.022) and TC levels (R = − 0.22, P = 0.030). These results indicate that TMC3115 might exhibit beneficial effects on the serum cholesterol metabolism of subjects with dyslipidaemia through modulation of their intestinal microbiota. Trial registration: ChiCTR-OOC-16010271 Keywords Probiotic supplementation . Intestinal microflora . Hyperglycaemia . Dyslipidaemia
Ke Wang and Xiaohong Yu contributed equally to the present study. * Fang He [email protected] * Ming Li [email protected] 1
West China School of Public Health and Healthy Food Evaluation Research Center, Sichuan University, Chengdu 610041, Sichuan, People’s Republic of China
2
The Health Service Center of Huayang Community, Tian Fu New District, Chengdu 610213, Sichuan, People’s Republic of China
3
Hebei Inatural Biotech Co. Ltd., Shijiazhuang 050800, Hebei, People’s Republic of China
4
ReGenera R&D International for Aging Intervention and San Babila Clinic, Corso Matteotti, 1/A, 20121 Milan, Italy
5
Department of Nutrition, Food Safety and Toxicology, West China School of Public Health, Sichuan University, No.16 People’s South Road, Chengdu 610041, Sichuan, People’s Republic of China
Intr
Data Loading...
